Cambridge, MA, United States of America

Holm Schneider


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Holm Schneider: Innovator in Ectodermal Dysplasias Treatment**

Introduction

Holm Schneider, a notable inventor based in Cambridge, MA, has made significant strides in the field of medical innovation. With a keen focus on ectodermal dysplasias, he has developed a patented method that presents a new approach to treatment for conditions that have long posed challenges in clinical environments.

Latest Patents

Holm Schneider holds a patent for his invention titled “Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias.” This groundbreaking invention pertains to methods for the intra-amniotic administration of EDA agonists, specifically EDI200. The techniques described in the patent enable the design of targeted therapeutic dosing and administration regimens aimed at correcting or altering abnormal phenotypes associated with ectodermal dysplasias, particularly X-linked Hypohidrotic Ectodermal Dysplasia (XLHED).

Career Highlights

Throughout his career, Holm Schneider has contributed to the medical field through his innovative thinking and dedication to addressing significant healthcare challenges. His work has culminated in advancements that may enhance treatment options for patients suffering from rare genetic disorders.

Collaborations

During his professional journey, Holm Schneider has collaborated with notable colleagues, including Pascal Schneider and Kenneth M. Huttner. His associations with distinguished organizations such as Espoir XLHED Sàrl and Friedrich-Alexander-Universität Erlangen-Nürnberg have further paved the way for impactful research and development in his field of specialization.

Conclusion

Holm Schneider's contributions to the medical community exemplify the power of innovation in addressing complex health issues. His patent for intra-amniotic administration of EDI200 showcases his commitment to advancing treatment options for ectodermal dysplasias, extending hope and improved outcomes to those affected by these conditions. With his ongoing efforts and collaborations, Schneider continues to make a lasting impact in the realm of medical inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…